More importantly, ACADL acted as a more powerful prognostic biomarker in HCC patients with YAP expression than those with no YAP expression, indicating that low ACADL expression promoted HCC growth and progression mainly through activating YAP. Here, ACADL is linked to hepatocellular carcinoma.